Stockman Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-9,528
Closed -$712K 168
2020
Q1
$712K Sell
9,528
-55,858
-85% -$3.86M 0.32% 63
2019
Q4
$4.25M Buy
65,386
+1,382
+2% +$90K 1.51% 22
2019
Q3
$4.06M Buy
64,004
+4,610
+8% +$301K 1.56% 20
2019
Q2
$4.01M Buy
59,394
+2,583
+5% +$170K 1.64% 21
2019
Q1
$3.69M Buy
56,811
+3,405
+6% +$226K 1.61% 23
2018
Q4
$3.34M Buy
53,406
+1,566
+3% +$109K 1.6% 23
2018
Q3
$4M Sell
51,840
-1,775
-3% -$134K 1.73% 20
2018
Q2
$3.8M Buy
53,615
+3,661
+7% +$259K 1.74% 21
2018
Q1
$3.77M Sell
49,954
-1,041
-2% -$82.8K 1.72% 21
2017
Q4
$3.65M Sell
50,995
-476
-0.9% -$36.1K 1.64% 21
2017
Q3
$4.17M Buy
51,471
+25,944
+102% +$1.98M 1.99% 13
2017
Q2
$1.81M Sell
25,527
-26,503
-51% -$1.76M 1.8% 16
2017
Q1
$3.53M Buy
52,030
+9,173
+21% +$645K 2.01% 13
2016
Q4
$3.07M Buy
42,857
+2,354
+6% +$175K 1.87% 17
2016
Q3
$3.21M Buy
40,503
+10,225
+34% +$831K 1.99% 16
2016
Q2
$2.53M Buy
+30,278
New +$2.69M 1.98% 19

Other funds holding GILD

Stockman Wealth Management's GILD Position: Q2 2020 in Review

Stockman Wealth Management sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 9,528 shares — an estimated $712K sold.

Stockman Wealth Management first reported a position in GILD in Q2 2016 and held it in 16 quarters. The position peaked at $4.25M in Q4 2019. 1,625 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • Stockman Wealth Management reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • Stockman Wealth Management sold 9,528 Gilead Sciences shares in Q2 2020, an estimated $712K.
  • Stockman Wealth Management first reported a position in Gilead Sciences in Q2 2016 and held it in 16 quarters.
  • Stockman Wealth Management's Gilead Sciences position peaked at $4.25M in Q4 2019.
  • 1,625 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Stockman Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.